The first edition of the Botton-Champalimaud International Pancreatic Conference, hosted at the prestigious Botton-Champalimaud Pancreatic Cancer Centre, was a landmark event in 2024, bringing together leading experts, researchers, and healthcare professionals from around the world to discuss the latest advancements in pancreatic cancer diagnosis, treatment, and care.

Host

Naz Belkaya, MSc, Circuit Dynamics and Computation

Venue

Seminar room

It was a happy coincidence: the final text of the Recommendations of the Multidisciplinary and Multiprofessional Working Group on the Clinical Use of Psychedelic Substances was released on the same day that the Portuguese National Health System announced its decision to fully reimburse the treatment of resistant depression with a substance called esketamine.

[PLEASE NOTE THAT THE RECRUITMENT PROCESS FOR THIS CALL IS NOW CLOSED]

Position overview

We are seeking a highly motivated and skilled Post-Doctoral Fellow to join our dynamic research team at the Botton-Champalimaud Pancreatic Cancer Centre. This prestigious center is dedicated to advancing pancreatic cancer research and treatment through innovative approaches and multidisciplinary collaboration.

[PLEASE NOTE THAT THE RECRUITMENT PROCESS FOR THIS CALL IS NOW CLOSED]

Offer Description

A Call for one research fellowship (Bolsa de Investigação) for a Game/VR Developer is open at Fundação D. Anna de Sommer Champalimaud e Dr.

Host

Ana Luísa Correia, PhD, Cancer Dormancy & Immunity

Venue

Seminar room

An international team, led by researchers at the Champalimaud Foundation (CF), has shown – for the first time in a realistic way – that it may be possible, in the future, to diagnose Parkinson’s disease (PD) years earlier, by scanning people’s brains with functional magnetic resonance imaging (fMRI). Although there are treatment options after diagnosis, there is no cure.  Therapies are continually improving — with ongoing research aiming to slow or even alter the course of the disease - investing in the research of methods that enable much earlier diagnosis is crucial.

Analysing these scans can also be time-consuming and complex, as doctors need to pore over countless images, looking for often tiny details.

So, any new imaging analysis technique that is faster and more precise is always welcome: a new paper (recently published in the Journal of Nuclear Medicine) reveals that the Champalimaud Foundation’s Nuclear Medicine-Radiopharmacology Unit has managed just that by using Deep Learning (DL) Artificial Intelligence (AI).